00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Eli Lilly finalized a $2.75 billion agreement to bring AI-developed drugs from InSilico
00:08Medicine to the global market, according to CNBC. The deal includes $115 million upfront,
00:15milestone payments, and royalties. InSilico has developed at least 28 drugs using generative AI,
00:21with nearly half in clinical stages. The partnership began with a software licensing
00:26deal in 2023 and aims to accelerate drug discovery. InSilico conducts AI work in Canada and the
00:33Middle East, while early development occurs in China. InSilico CEO Alex Zavronkov said Eli Lilly
00:39integrates biology, chemistry, and automation in AI development. The company will join Lilly's
00:45gateway labs under the agreement. For all things money, visit Benzinga.com.
Comments